PALISADE BIO Business Summary

Palisade Bio Inc. (PALI) is a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics to protect intestinal barrier integrity and treat gastrointestinal (GI) disorders. The company’s revenue model is predicated on intellectual property licensing, clinical milestone achievements, and strategic research collaborations, with current operations focused on its proprietary gut-restricted prodrug platform. Its primary business segments are defined by its lead candidate, PALI-2108—a microbiota-activated, oral PDE4 inhibitor prodrug for ulcerative colitis and fibrostenotic Crohn’s disease—and its earlier-stage PALI-1908 program. Palisade Bio operates within a competitive landscape that includes Ventyx Biosciences, Ironwood Pharmaceuticals, and Fortress Biotech. It maintains a distinct market position by leveraging localized delivery mechanisms designed to maximize therapeutic efficacy in the colon while minimizing the systemic side effects common in broader immunosuppressive treatments. Formed through the 2021 merger of Leading BioSciences and Seneca Biopharma, Palisade Bio is led by CEO JD Finley, an experienced financial strategist who previously served as the company’s CFO and has facilitated nearly $1 billion in capital raises throughout his career. The scientific and clinical direction is overseen by President and Chief Medical Officer Dr. Mitch Jones, MD, Ph.D., a biotech entrepreneur with a pedigree including leadership tenures at Chemomab, Finch Therapeutics, and Biora Therapeutics, and the founding of Interface Therapeutics. The executive suite is further supported by Ryker Willie (SVP, Finance) and Sharon Skare (VP, Global Head of Clinical Operations). The company’s strategic trajectory is guided by a board chaired by Donald A. Williams and is supported by prominent institutional investors such as Perceptive Advisors, Commodore Capital, and the Crohn's & Colitis Foundation.